About Us

Science-Led
Regenerative Medicine

The body holds the blueprint for its own repair. We develop products that harness extracellular matrix, the natural signaling network within tissues, to restore function following injury and disease.

Our Approach

01

Science-Driven

Every decision rooted in rigorous research and clinical evidence

02

Biologically Intelligent

Therapies designed to work with natural healing processes

03

Patient-Focused

Meaningful clinical outcomes that restore function

04

Innovation-Minded

Pushing boundaries in regenerative medicine

Extracellular Matrix-based Therapy Development Timeline

1995

The Badylak lab develops the first bioscaffold for use as a surgical mesh applications

1995 Research
1999

FDA approval of the first ECM-based bioscaffold.

FDA Approval Graphic
2008

Tunable ECM hydrogels from decellularized ECM were discovered by the Badylak Laboratory at University of Pittsburgh

Hydrogel Research
75+ publications generated
on ECM-based therapies
2016

The Badylak laboratory discovered Matrix-Bound Nanovesicles (MBV) embedded within ECM Bioscaffolds.

MBV Discovery
2018

Launch of ECM Therapeutics to commercialize injectable ECM Hydrogel and Matrix-Bound Nanovesicles (MBV) therapies

ECM Therapeutics Headquarters
Nov 2025

Submission of 510(k) application for ECM hydrogel for wound management.

FDA Clearance Graphic
Dec 2025

Initiation of IDE clinical study evaluating injectable ECM hydrogel for anorectal fistula repair.

IDE clinical study
Leadership

Our Team

Guided by decades of scientific research and clinical expertise in regenerative medicine.

Dr. Stephen Badylak

Dr. Stephen Badylak, DVM, PhD, MD

Founder & Chief Medical Officer

Dr. Stephen Badylak, DVM, PhD, MD is a Professor in the Department of Surgery, and Deputy Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.

Dr. Badylak has practiced both veterinary and human medicine and for the past 20 years has been fully engaged in research. Dr. Badylak began his academic career at Purdue University in 1983, and subsequently held a variety of positions including service as the Director of the Hillenbrand Biomedical Engineering Center from 1995-1998.

Dr. Badylak holds over 60 U.S. patents, 300 patents worldwide, has authored more than 350 scientific publications and 40 book chapters, and has recently edited a textbook entitled "Host Response to Biomaterials". He has served as the Chair of several study sections at the National Institutes of Health (NIH), and is currently a member of the College of Scientific Reviewers for NIH. Dr. Badylak has either chaired or been a member of the Scientific Advisory Board to several major medical device companies. More than eight million patients have been treated with bioscaffolds developed in Dr. Badylak's laboratory.

Dr. Badylak is a Fellow of the American Institute for Medical and Biological Engineering, a member of the Society for Biomaterials, a charter member of the Tissue Engineering Society International, a past president of the Tissue Engineering Regenerative Medicine International Society (TERMIS) and a Founding International Fellow of TERMIS.

Paul Fagan Headshot

Paul Fagan, JD, MBA, CPA

Chief Executive Officer

Paul commenced serving as the Chief Executive Officer of ECM Therapeutics since April, 2018. Prior to ECM Therapeutics, in 2000 Paul co-founded and served as Executive Vice President and General Counsel of Three Rivers Pharmaceuticals, LLC ("3RP") as well as being a member of its Board of Directors.

Prior to 3RP, Paul was a shareholder in the law firm of Tucker Arensberg, P.C. from 1994 through November 2000 and an associate with that same firm from 1990 to 1994. Prior to that, Paul was a tax professional with the international accounting firm of Ernst and Young, LLP. Paul is also a Certified Public Accountant.

Paul was a recipient of the Ernst & Young Entrepreneur of the Year Award in 2006 for the Upstate New York & Western Pennsylvania Region.

Russ Kronengold Headshot

Russ Kronengold, PhD

Chief Science Officer

Dr. Kronengold has served as Chief Science Officer for ECM Therapeutics since May 2025. He has over 30 years of experience in the regenerative medicine industry, primarily in the design, development, and commercialization of ECM and collagen-based biomaterials. Dr. Kronengold founded a consulting business specializing in regenerative medicine in 2013, with clients representing biological wound care, orthopaedics and spine, hemostasis, general and plastic surgery, cardiology, and other medical fields.

Prior to consulting, Dr. Kronengold was the Chief Science Officer at Aperion Biologics, Inc. (ABI), where he led R&D efforts that resulted in the CE Mark for Z-Lig™, the first engineered biological device designed for ACL reconstruction to be approved anywhere worldwide.

Dr. Kronengold holds a Ph.D. and M.S. in Biomedical Engineering from UMDNJ-Robert Wood Johnson Medical School / Rutgers University and a B.S. in Chemical Engineering from Carnegie Mellon University.

Katie Collins

Katie Collins

Co-Founder, Vice President, Business Development

Prior to co-founding ECM Therapeutics, Katie founded and remains President of KLC Connections, a business development and marketing firm that specializes in biotechnology and medical industries. Prior to starting her own firm, she was recruited by Dr. Craig Venter, who is known for sequencing the human genome, to lead the fundraising efforts of the J. Craig Venter Institute from 2012-2016. In that timeframe, the institute raised over 13M in philanthropic support.

Before working for JCVI, she worked at The Scripps Research Institute for 10 years where she held various leadership roles within Human Resources and the Philanthropy departments. In that time, Katie developed an extensive network of biotech industry leaders, scientific leaders and high-net worth investors. She was awarded a swimming scholarship from Penn State University, where she graduated with a business degree in Health Policy and Administration.